Here's Why Vir Biotechnology Jumped 12% in May
What happened Shares of Vir Biotechnology (NASDAQ: VIR) rose 12% in May, according to data provided by S&P Global Market Intelligence, after the biotech published preclinical data in the journal Nature on S309, a monoclonal antibody that appears to target SARS-CoV-2, the novel coronavirus that causes COVID-19.